In conclusion, contrary to many preclinical studies, targeted intravenous albumin therapy in hospitalized patients with decompensated cirrhosis had no effect across a broad range of markers of systemic inflammation, albumin binding and oxidation, and cardiovascular function using samples from our large prospective, completed randomized and appropriately powered trial. Here, ALB is linked to Cirrhosis.